In advanced prostate cancer, when patients become resistant to first-line classical androgen deprivation therapy, alternative options, besides chemotherapy, do exist.
Abiraterone and Enzalutamide are recently developed hormonal treatments which have demonstrated benefit in survival. Ian Tannock explains how to use these drugs and when chemotherapy should be recommended in castration-resistant prostate cancer patients.
Attard et al, J Clin Oncol 2008;26:4563-71. Reprinted with permission. © 2008. American Society of Clinical Oncology. All rights reserved.
Tran et al: Science 2010;324:787-90. Reprinted with permission. © 2010, American
Association for the Advancement of Science. All rights reserved.
Antonarakis et al: N Engl J Med 2014;371:1028-38. Reprinted with permission. Copyright © 2014, Massachusetts Medical Society. All rights reserved.
Produced by the European Society for Medical Oncology
oncologypro.esmo.org